This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D64.4 | Synonyms: CDA, Congenital dyserythropoietic anaemia, congenital ineffective erythropoiesis anemia
Congenital dyserythropoietic anemia (CDA) was first described as an independent disease entity by Wendt and Heimpel in 1966. They classified anemic patients showing distinctive dysplastic findings in the bone marrow, such as multinuclear erythroblasts and internuclear chromatin bridges, and named this "congenital dyserythropoietic anemia."
In 1968, Heimpel and Wendt proposed a system classifying CDA into types I, II, and III based on bone marrow morphological features and serological findings. This classification system is still used as the foundation of CDA diagnosis. Additional subtypes (CDA type IV, CDA type X, etc.) were later described with advances in molecular genetic techniques.
In 2002, CDAN1 (codanin-1) was identified as the causative gene of CDA type I, and in 2009 SEC23B was identified as the causative gene of CDA type II, revealing that a defect in the COPII vesicle transport protein causes impaired red cell maturation.
In Korea, CDA is a very rare disease, published in the form of individual case reports. Most are diagnosed as type I or type II, and accurate molecular genetic diagnosis is gradually becoming possible.
The most common cause of CDA type I is variants in the CDAN1 gene (15q15.2, autosomal recessive). CDAN1 encodes the codanin-1 protein, which functions as a histone chaperone (interacting with CHAF1B) and in DNA replication. Variants in the C15ORF41 gene also cause CDA type I.
CDA type II (HEMPAS) is caused by variants in the SEC23B gene (20p11.21, autosomal recessive). SEC23B is a component of the COPII vesicle coat complex and is involved in protein transport from the endoplasmic reticulum to the Golgi apparatus. Loss of SEC23B function causes abnormal glycosylation of red cell membrane glycoproteins.
CDA type III is caused by KIF23 gene variants (autosomal dominant), and dysfunction of the MKLP-1 (kinesin family member 23) protein leads to formation of multinucleated giant erythroblasts. Other reported causative genes are KLF1/EKLF (CDA type IV, autosomal dominant) and GATA1 (CDAX, X-linked).
| Subtype | Causative gene | Chromosomal location | Mode of inheritance |
|---|---|---|---|
| CDA type I | CDAN1, C15ORF41 | 15q15.2 | Autosomal recessive |
| CDA type II (HEMPAS) | SEC23B | 20p11.21 | Autosomal recessive |
| CDA type III | KIF23 | 15q23 | Autosomal dominant |
| CDA type IV | KLF1/EKLF | 19p13.2 | Autosomal dominant |
| CDAX | GATA1 | Xp11.23 | X-linked |
The CDAN1 p.R1042W variant in CDA type I shows a high carrier frequency among Ashkenazi Jews due to a founder effect. The SEC23B p.E109K variant in CDA type II is frequently reported in southern Italy due to a founder effect.
Clinical severity varies even with the same gene variant, reflecting additional gene variants (modifier genes), environmental factors, and genotype-phenotype complexity. In the case of SEC23B, severity differs greatly by variant type.
CDA is an extremely rare disease; an estimated fewer than about 500–1,000 patients are registered worldwide. The exact prevalence is likely underestimated because of diagnostic difficulty.
CDA type II is the most common, accounting for 60–70% of all CDA. The frequency of CDA type II is relatively high in Mediterranean regions such as Italy and Spain. CDA type I accounts for 20–30% of the total and is frequent among Ashkenazi Jews. CDA type III is very rare, and a high-frequency kindred has been reported in a rural area of northern Sweden.
In Korea, separate epidemiological data on CDA are limited, and it is identified through individual case reports. It is managed within the rare disease registration system and is mainly diagnosed at tertiary hospitals capable of molecular genetic diagnosis (Seoul National University Hospital, Samsung Medical Center, etc.).
The core pathogenesis of CDA is ineffective erythropoiesis. Proliferation of erythroblasts in the bone marrow is normal or increased, but because of dysplasia and abnormal cell division during maturation, most erythroblasts are abnormally destroyed within the bone marrow (intramedullary hemolysis).
The CDAN1 protein (codanin-1) binds to the B subunit of the histone chaperone CAF-1 (CHAF1B) and assists chromatin assembly after DNA replication. With loss of function, defects in chromatin structure formation arise in erythroblasts, causing intranuclear cavity formation ("Swiss cheese" dysplasia) and internuclear chromatin bridges.
With SEC23B dysfunction, protein transport via COPII vesicles decreases, and red cell membrane glycoproteins (band 3, band 4.5, etc.) are abnormally glycosylated. Formation of double membranes (cisternae) in binucleated and multinucleated erythroblasts is characteristic.
KIF23 (MKLP-1) is located at the central spindle and is involved in spindle completion and initiation of cytokinesis during cell division. With dysfunction, cytokinesis cannot be completed, forming giant cells (gigantoblasts) containing up to 12 nuclei.
Fatigue, reduced exercise tolerance, pallor, and dizziness are common symptoms. Jaundice (scleral icterus) reflects increased indirect bilirubin due to ineffective erythropoiesis. Abdominal pain due to gallstones may recur.
Even without transfusion, iron overload progresses slowly because of ineffective erythropoiesis. It can cause liver fibrosis, reduced cardiac function, and endocrine dysfunction (diabetes, hypothyroidism, growth delay).
Pallor, jaundice (including scleral icterus), splenomegaly, and hepatomegaly are the main physical findings. The skin may become yellowish-brown (iron overload). In CDA type I, finger and toe malformations (polydactyly, brachydactyly, syndactyly) may be observed.
| Subtype | Light microscopy findings | Electron microscopy findings | Serology |
|---|---|---|---|
| CDA type I | Internuclear chromatin bridges, binucleated erythroblasts, Swiss cheese chromatin | Chromatin cavities, abnormal nuclear membrane–endoplasmic reticulum connections | Ham test negative |
| CDA type II | Binucleated to multinucleated (up to 5 nuclei) erythroblasts, frequent in polychromatophilic cells | Double membranes (double cisternae) | Ham test positive, strong i antigen expression |
| CDA type III | Giant multinucleated erythroblasts with up to 12 nuclei (gigantoblasts) | Failure to complete nuclear division | Generally normal |
Normocytic or macrocytic anemia; reticulocyte count inappropriately low or mildly increased; elevated indirect bilirubin, elevated LDH, decreased haptoglobin (hemolysis markers); elevated serum ferritin and serum iron (iron overload).
CDA is suspected in the following situations: ① chronic anemia of unknown cause in childhood to adolescence; ② anemia with a reticulocyte count low relative to hemolysis markers; ③ anemia accompanied by splenomegaly and jaundice; ④ anemia requiring repeated transfusions with a negative family history; ⑤ similar anemia in family members.
CBC and absolute reticulocyte count; peripheral blood smear; hemolysis markers (LDH, bilirubin, haptoglobin, urobilinogen); serum ferritin and transferrin saturation.
Ham test (acidified serum hemolysis test): limited sensitivity but usable as low-cost screening. Flow cytometry (CD55/CD59, i antigen): distinguishes CDA type II from PNH.
Bone marrow morphological examination is the core of CDA diagnosis. Subtype-specific findings are confirmed by light and electron microscopy. Internuclear chromatin bridges (CDA type I), binucleated and multinucleated erythroblasts and double membranes (CDA type II), and giant multinucleated erythroblasts (CDA type III) are identified.
Molecular genetic testing is essential for definitive diagnosis and subtype classification of CDA. Sequencing of the CDAN1, C15ORF41 (CDA type I), SEC23B (CDA type II), KIF23 (CDA type III), KLF1 (CDA type IV), and GATA1 (CDAX) genes or NGS panel testing is performed.
Hemoglobin electrophoresis/HPLC (to exclude thalassemia and sickle cell anemia); red cell enzyme tests (to exclude G6PD deficiency and pyruvate kinase deficiency); direct antiglobulin test (DAT, to exclude immune hemolysis); flow cytometry (to exclude PNH); cytogenetic testing and somatic variant NGS to exclude MDS.
Transfusion may not be needed in mild CDA, but packed red cell transfusion is given for moderate or greater anemia (Hb <7 g/dL) or when symptoms are present. Minimizing the number of transfusions is important for preventing iron overload.
Non-transfusional iron overload results from increased intestinal iron absorption due to ineffective erythropoiesis and occurs regardless of transfusion. Iron chelators such as deferoxamine, deferasirox, and deferiprone are given according to serum ferritin levels.
Interferon-alpha (IFN-α) treatment in CDA type I has been reported in some cases to reduce ineffective erythropoiesis and improve anemia. The response rate is about 60–70%.
Splenectomy is performed for increased transfusion requirements due to hypersplenism or for severe splenomegaly. In severe CDA (especially severe CDA type I), allogeneic HSCT from an HLA-matched donor is considered as a treatment option.
Reduced cardiac function, liver cirrhosis, and endocrine complications due to iron overload are the main long-term complications. Normalization of life expectancy is possible in patients receiving appropriate iron chelation therapy. With successful HSCT, a curative outcome can be expected. Blood tests every 6 months, and liver MRI T2* (quantification of iron overload), echocardiography, and endocrine function tests every 1–2 years are performed.
Because CDA is a genetic disease, genetic counseling must be provided after diagnosis. For autosomal recessive types (CDA types I and II), confirmation of parental carrier status and testing of siblings are recommended. For future pregnancies, prenatal genetic testing (CVS or amniocentesis) or preimplantation genetic testing (PGT-M) is possible.
Increased intestinal iron absorption due to ineffective erythropoiesis should be recognized early, and iron chelation should be started before serum ferritin reaches >1,000 μg/L. Unnecessary iron supplements and excessive vitamin C intake should be avoided.
After splenectomy, vaccination against encapsulated bacteria (pneumococcus, meningococcus, Haemophilus influenzae) and prophylactic antibiotics (penicillin). Early surgical treatment when gallstones develop. Prevention of acute worsening of anemia through early treatment of infections.